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Purified N 54 kDa plasminogen activator inhibitor from human fibrosarcoma cells was converted to an inac- 
tive form with slightly higher electrophoretic mobility by incubation with catalytic amounts of urokinase- 
type or tissue-type plasminogen activator. Serine proteinase inhibitors and a monoclonal antibody against 
urokinase-type plasminogen activator inhibited the conversion, indicating that it was caused by plasmin- 
ogen activator-catalyzed proteolysis. These findings represent he first demonstration of a well-defined pro- 
tein apart from plasminogen, constituting a substrate for plasminogen activators. 
PI~minogen activator Enzyme inhibitor (HT-1~8O~brosarcoma cell) 
1. INTRODUCTION 
Plasminogen activators catalyse the cleavage of 
a single peptide bond in plasminogen, thereby con- 
verting it to the active proteinase plasmin. Two 
types of plasm~nogen activators exist. They are 
both serine proteinases, and products of different 
genes, and presumably have different biological 
functions. u-PA is among other functions sup- 
posed to be involved in tissue degradation and 
t-PA is a key enzyme in thrombolysis (for reviews, 
see [l-5]). 
Inhibitors of plasminogen activators have been 
identified in a variety of tissues and cell types 
(16-241, see 15,251 for reviews). We have recently 
reported that the human fibrosarcoma cell line 
HT-1080 releases an -54 kDa protein that inhibits 
u-PA and t-PA, but not plasmin, and has the same 
mobility in SDS-PAGE as plasminogen activator 
Abbreviations: u-PA, urokinase-type plasminogen ac- 
tivator; pro-u-PA, proenzyme to urokinase-type 
plasminogen activator; t-PA, tissue-type plasminogen 
activator; SDS-PAGE, SDS-polyacrylamide gel elec- 
trophoresis 
inhibitors present in endothelial cells and blood 
platelets 126,271. We now report that catalytic 
amounts of u-PA and t-PA convert this inhibitor 
to an inactive form with a slightly higher elec- 
trophoretic mobility. 
2. MATERIALS AND METHODS 
Conditioned serum-free culture fluid from the 
human fibrosarcoma cell line HT-1080 was 
prepared as reported for other cell lines [28], ex- 
cept that the cells were cultured in the presence of 
10e6 M dexamethasone to increase inhibitor pro- 
duction [26]. Human pro-u-PA was prepared from 
the conditioned culture fluid of HT-1080 cells by 
affinity chromatography with a monoclonal an- 
tibody [29]. Active u-PA, plasminogen and 
plasmin were prepared as described [30,31]. Rab- 
bits were immunized with plasminogen activator 
inhibitor purified from conditioned culture fluid 
from HT-1080 cells by affinity chromatography on 
concanavalin A-Sepharose [17,26] followed by 
preparative SDS-PAGE [26]. Antibodies were 
purified from rabbit serum using affinity 
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chromatography on protein A-Sepharose as 
described [32]. 
The plasminogen activator enzyme activity was 
determined by the r2”I-fibrin plate assay as de- 
scribed [28], using 1 h incubation at 37”C, 500,ui 
assay buffer consisting of 0.1 M Tris-HCI, pH 8.1, 
0.1% Triton X-100, 0.25% gelatin and urokinase 
(LEO, Ballerup, Denmark) as a standard. This 
assay was modified for quantitation of inhibitor as 
described [27]. Before assay, inhibitor prepara- 
tions (-80~glml) were treated with 0.1% SDS 
(final concentration) for 1 h at 25°C to enhance in- 
hibitory activity [23]. Triton X-100 was then added 
to a final concentration of 1%. 
SDS-PAGE was carried out in slab gels with a 
linear 6-16% polyacrylamide concentration gra- 
dient as described [33]. When necessary samples 
were concentrated by trichloroacetic acid 
precipitation before electrophoresis. The gels were 
either stained with Coomassie blue or processed 
for reverse zymography for the detection of u-PA 
inhibitors by a modification [14,26] of the 
zymographic technique described by Graneili- 
Piperno and Reich 1341. Inhibitors diffused into an 
agarose gel containing u-PA, plasminogen and 
fibrin, and their presence was revealed by lysis- 
resistant zones. Protein concentration in purified 
concentrated inhibitor preparations was estimated 
with the folin-Ciocalteu phenol reagent. At1 
reagents were as described [26,28,30,32,35,36] or
of the best grade commercially available. 
Fig, 1. SDS-PAGE followed by Coomassie blue staining 
(a,b) or reverse zymography (a’,b’) of plasminogen 
activator inhibitor from culture fluid of HT-1080 cells 
before (a,a’) and after (b,b’) purification by affinity 
chromato~aphy on a column of Sepharose-conjugated 
rabbit antibodies against the inhibitor. 250 ml culture 
fluid from dexamethasone-treated HT-1080 cells were 
applied to a 25 ml Sepharose column containing 250 mg 
rabbit anti-inhibitor IgG and equilibrated with 0.1 M 
Tris-HCl, pH 8.1, 0.01% Tween 20. The column was 
washed with 50 ml equilibration buffer, followed by 
80 ml of the same buffer supplemented with 1 M NaCl. 
Elution was performed with 0.1 M CH&OOH, pH 2.9, 
1 M NaCl, 0.01% Tween 20 in 5 ml fractions into tubes 
containing 0.75 ml of 1 M Tris-HCI, pH 9.0. The eluate 
contained 101 ~g protein and 52% of the inhibitory 
activity applied to the column. 1.5 ml (a) or 40~1 (a’) 
culture fluid and 10 pg (b) or 0.2 pg (b’) purified protein 
were applied to the gel. The positions of &marker 
3. RESULTS 
proteins are indicated. 
-54 kDa human plasminogen activator in- Incubation of the purified SDS-treated inhibitor 
hibitor from serum-free culture fluid from the with catalytic amounts of u-PA led to its dose- 
HT-1080 cell line was purified by chromatography dependent conversion to a form with a slightly in- 
on a Sepharose column coupled with rabbit an- creased mobility in SDS-PAGE under non- 
tibodies against the inhibitor. The purified reducing (fig.2) as well as reducing (not shown) 
preparation contained one Coomassie blue- conditions. No conversion was observed when 
stainable band after SDS-PAGE under non- SDS-treatment of the inhibitor was omitted, when 
reducing (fig.11 as well as reducing (not shown) p-aminobenzamidine, p-nitrophenyl-~ ‘ -guanidi- 
conditions, indicating that the inhibitor consists of nobenzoate (both inhibitors of u-PA; see [33]), or 
one polypeptide chain. The apparent molecular a monoclonal antibody to u-PA (previously found 
mass as based on the electrophoretic mobility was to inhibit the proteolytic activity of u-PA [29]) was 
-54 kDa under both non-reducing and reducing added, or when u-PA was substituted by its proen- 
conditions. Under non-reducing conditions the zyme. Bovine pancreatic trypsin inhibitor did not 
electrophoretic mobility of the stained band was inhibit the conversion caused by incubation with 
indistinguishable from that of the inhibitory activi- u-PA (fig.2). t-PA caused a similar conversion of 
ty as determined by reverse zymography (fig.1). the inhibitor, while plasmin caused a conversion to 
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Fig.2. SDS-PAGE of inhibitor incubated without 
plasminogen activator (b), with u-PA (a,c-h) or pro-u- 
PA (i). Inhibitor purified as described in the legend to 
fig.1 was preincubated without (a) and with SDS (b-i), 
followed by incubation (500~1 total volume, 4 pg 
inhibitor/ml) for 2 h at 37°C in 0.1 M Tris-HCI, pH 8.1; 
0.1% Triton X-100 with u-PA: 0.0008 (c), 0.004 (d), 
0.02 (e), 0.1 pg/ml (a,f-h), 0.1 rg/ml pro-u-PA (i) and 
lOpg/ml monoclonal anti-u-PA IgG clone 2 (g) or 
25 ,ug/ml bovine pancreatic trypsin inhibitor (h). After 
electrophoresis the gel was stained with Coomassie blue. 
Incubation of sample f with p-aminobenzamidine 
(5 mM) or p-nitrophenyl-p’ -guanidinobenzoate (100 
FM) gave results identical to those shown in lane g. A 
monoclonal antibody of irrelevant specificity (anti- 
trinitrophenyl) had no effect on the conversion (not 
shown). When u-PA in sample f was substituted with 
t-PA (0.1 &g/ml) identical results were obtained (not 
shown). Incubation of sample b with plasmin (0.2pg) 
resulted in a partial conversion to several polypeptides 
with M, values below 45000. This effect was completely 
abolished by bovine pancreatic trypsin inhibitor (25 
#g/ml). Incubation of sample b with less than 0.02 
pg/ml plasmin did not lead to detectable conversion. 
Inhibitor preparations which were preincubated with 
SDS and not incubated with u-PA were indistinguishable 
from that shown in lane a. 
several ~lypeptides that migrated faster than the 
one formed by the plasminogen activators. Results 
similar to those shown in fig.2, lanes a and f, were 
obtained with u-PA and an inhibitor preparation 
purified by affinity chromatography with a mono- 
clonal antibody that neutralized its inhibitory ac- 
tivity (L.S. Nielsen, unpublished). 
The converted form of the inhibitor did not in- 
hibit u-PA activity as measured by the r2$fibrin 
10 
---O 
0.001 00t 0.1 t lo 
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Fig.3. Effect of non-converted (0) and converted (e) 
inhibitor on “‘I-fibrin plate assay for u-PA. SDS- 
treated inhibitor (9pg/ml) was incubated for 2 h at 
37°C in assay buffer without (0) or with (0) 0.1 p&/ml 
u-PA and passed twice through a l-ml column of 1 mg 
monoclonal anti-u-PA IgG clone 2 coupled to 
Sepharose. Analysis by SDS-PAGE of the preparations 
gave the results shown in fig.2 lanes b and f, 
respectively. The protein content was determined by 
spectrophotometric scanning of Coomassie blue stained 
gels, using purified non-converted inhibitor as a 
standard [27]. Inhibitor in various concentrations was 
preincubated with urokinase (200 mPU/ml) for 10 min 
at 4°C in assay buffer, diluted IO-fold with this buffer 
and assayed in the ‘2sI-fibrin plate assay. The final 
concentration of inhibitor during the assay is indicated. 
Control assays were performed identically except that 
inhibitor was omitted. In the control assay -7000 cpm 
per well were released corresponding to - 12% of the 
total radioactivity in each well. Background values 
without u-PA added (-500 cpm) have been subtracted. 
Inset: Reverse fibrin-agarose zymography of the non- 
converted (a) and converted (b) inhibitor preparations. 
50 ng protein was elcctrophoresed in each lane. 
plate assay or by zymography (fig.3). Neither did 
it inhibit t-PA in the “‘I-fibrin plate assay under 
similar conditions (not shown). 
4. DISCUSSION 
This study demonstrates that plasminogen ac- 
tivators catalyse conversion of HT-1080 plas- 
minogen activator inhibitor to an inactive form 
with an electrophoretic mobility in SDS-PAGE 
corresponding to an apparent M, slightly lower 
than that of the non-converted form. The conver- 
sion caused by u-PA was inhibited by inhibitors of 
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this enzyme (including the active site titrant 
p-nitrophenyl-p’-guanidinobenzoate) indicating 
that it was due to proteolysis directly involving the 
active site of u-PA. On the basis of the present 
data, it cannot be determined whether the observed 
change in electrophoretic mobility during conver- 
sion is only due to a decrease in M, as conforma- 
tional changes may also contribute. For a further 
clarification of this question, studies on the amino 
acid sequence of the two forms of the inhibitor are 
needed. Such studies are in progress, but have been 
hampered by the fact that the active form is N- 
terminally blocked (A. Henschen and L.S. Nielsen, 
unpublished). 
These findings provide the first unequivocal 
demonstration of a well-defined protein apart 
from plasminogen acting as a substrate for 
plasminogen activators. The existence of such 
substrates has been suggested previously [37,38], 
although the nature of the putative protein 
substrates was not determined. Our results raise 
the possibility that plasminogen activator in- 
hibitors have been involved in the effects observed 
in these studies. 
The present findings seem to indicate that the 
mechanism of action of this inhibitor deviates 
from the standard mechanism for inhibition of 
proteinases by protein inhibitors, where pro- 
teolysis of the inhibitors does not proceed to com- 
pletion and where the modified forms of the in- 
hibitors are active (reviews [39,40]). In these 
respects, this plasminogen activator inhibitor 
seems closer to some members of the cut-proteinase 
inhibitor class [40]. 
The HT-1080 inhibitor forms an SDS-resistant 
complex with the active form of u-PA, but not 
with pro-u-PA [26]. The u-PA/inhibitor complex 
has an apparent plasminogen activator activity as 
revealed by zymography after SDS-PAGE, where 
plasminogen activators diffuse into and cause lysis 
zones in agarose gels containing plasminogen and 
fibrin [26]. Similar findings have been reported for 
complexes of plasminogen activaturs and in- 
hibitors from other sources ([ 13,15-20,231; T.D. 
Gelehrter, personal communication). The present 
results offer a likely explanation for the apparent 
activity of the complexes. During the zymography, 
the plasminogen activator degrades the inhibitor to 
its inactive form, the complex is dissociated and 
the plasminogen activator regains its activity. 
272 
The physiological role of the -54 kDa protein 
described here remains to be clarified. Apart from 
its possible function as a physiological inhibitor of 
plasminogen activators, it may be speculated that 
either itself, its -50 kDa conversion product or the 
putative released peptide, might have other 
functions. 
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